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ABSTRACT
Purpose: Metastatic renal cell carcinoma (RCC) is one of the most treatment-resistant malignancies and nephrectomy, 
isolated or combined with systemic chemotherapy typically has limited or no effectiveness. We report our initial results 
in patients treated with the association of molecular targeted therapy, nephrectomy, and hybrid dendritic-tumor cell (DC) 
vaccine.
Materials and Methods: Two male patients diagnosed with metastatic RCC were selected for the study. They were treated 
with the triple strategy, in which sunitinib (50 mg per day) was given for 4 weeks, followed by radical nephrectomy after 
two weeks. DC vaccine was initiated immediately after surgery and repeated monthly. Sunitinib was restarted daily after 
2 to 3 weeks of surgery with a 7-day interval every 4 weeks.
Results: Both patients had complete adherence to the proposed treatment with DC vaccine therapy combined with sunitinib. 
Follow-up in these patients at 9 and 10 months demonstrated a stable disease in both, as shown by imaging and clinical 
findings, with no further treatment required.
Conclusion: The immune response obtained with DC vaccine combined with the antiangiogenic effect of sunitinib and 
the potential benefits of cytoreductive nephrectomy in advanced disease could represent a new option in the treatment of 
metastatic RCC. Further prospective trials are needed not only to elucidate the ideal dosing and schedule, but also to better 
define the proof-of-concept proposed in this report and its role in clinical practice.
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INTRODUCTION
 Renal cell carcinoma (RCC), the most com-
mon type of kidney cancer, is commonly asymp-
tomatic in its early stages. Consequently, 25-30% of 
patients are diagnosed with metastatic disease at initial 
presentation. The incidence of RCC has grown at a 
rate of 3.7% in recent years (1). The etiology of RCC 
is still widely unknown and the disease primarily af-
fects men and women in the fifth and sixth decades of 
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life (2). It is characterized by a lack of early warning 
signs and diverse clinical manifestations. RCC has 
historically been a difficult malignancy to diagnose 
and also to treat, because it remains clinically occult 
for most of its course. It is often diagnosed inciden-
tally following radiologic studies. In advanced stages, 
treatment results are extremely poor, with response 
rates for treated patients remaining between 5% to 
10% and overall median survival of less than one year 
(3). The US National Cancer Institute has estimated 
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approximately 15.7 years of life lost per-person dying 
(4). The cytoreductive surgery (nephrectomy) and/or 
systemic treatment with cytotoxic chemotherapy typi-
cally have limited or no effectiveness (5).
 Recently, less-toxic molecular targeted thera-
pies have been the subject of clinical trials of advanced 
RCC, including sorafenib and sunitinib, which have 
shown survival benefits for patients with metastatic 
RCC. This strategy has become an important therapy 
option with promising results, such as extending life 
and bringing quality of life to these patients (6).
 Dendritic cells (DC) are potent antigen-pre-
senting cells and effective initiators of an invasive re-
sponse (7). The recent development of DC in vitro has 
opened new possibilities for cancer therapy. Kugler et 
al. were the first to demonstrate the possibility of DC 
to become a tumor vaccine for metastatic RCC (8). 
More recently, significant responses were reported in 
this disease stage with vaccines based on DC hybrid-
ized with cells from the tumor itself (9,10). However, 
trials evaluating vaccine-based therapies are still 
awaited. The use of vaccines in cancer, nonetheless, 
will initially only be possible in a combined approach, 
in which current strategies, surgery as a cytoreductive 
enhancer, and novel agents are included (11).
 Since the mechanism by which DC therapy 
strongly stimulates the patient’s immunologic sys-
tem greatly differs from that of the targeted-drug by 
anti-angiogenic effect, we attempted to assess the 
possible added or synergic combination of those two 
therapies.
 We report on our initial experience with 
patients treated with a multi-modality approach, in 
which we combined a molecular targeted drug, cy-
toreductive nephrectomy, and hybrid DC vaccine.
MATERIALS AND METHODS
 Two male patients presenting renal masses 
and systemic metastasis at first assessment were 
included in this analysis (Table-1).
 By the time of diagnosis, the patients already 
had several distant metastatic masses and bulky renal 
tumors on imaging studies (Figure-1). The treatment 
was initiated with sunitinib (50 mg per day) before 
surgery for 30 days. After two weeks, patients under-
went radical nephrectomy. DC vaccine was admin-
istered just after the surgery and monthly thereafter. 
The use of sunitinib was restarted after 2 to 3 weeks 
of surgery (Table-1).
 The DC vaccine was prepared and obtained 
as previously described (9,10). In summary, peripheral 
blood mononuclear cells were collected from healthy 
unrelated volunteers through apheresis, after informed 
consent of donors. Mononuclear cells were separated 
further with a density gradient, resuspended, and seeded 
in culture flasks in RPMI 1640 culture medium. Then, 
flasks were incubated at 37ºC for a period of 4 h, when 
nonadherent cells were removed, and the RPMI me-
dium was replaced by a serum-free medium containing 
GM-CSF (50 ng/mL; R&D, Minneapolis, MN, USA) 
and interleukin 4 (50 ng/mL; R&D, Minneapolis, MN, 
USA). After 5 days in culture, TNF-a (50 ng/mL; R&D, 
Minneapolis, MN, USA) was added to the cultures for 
DC activation. After 2 further days in culture, cells 
were harvested and used for the generation of the 
dendritic-tumor hybrid vaccine. At the last day of DC 
cultures, DCs were harvested, washed, and resuspended 
in a sterile 5% glucose solution at a concentration of 
1 107 cells/mL. Tumor cells were thawed, washed, 
and also resuspended in a sterile 5% glucose solution 
at a concentration of 1 107 cells/mL. These two cell 
suspensions were mixed at equal volumes, and cells 
were fused by an electric pulse. Shortly after fusion, all 
cells stained with trypan blue. The hybrid cell prepara-
tion was centrifuged, resuspended in 1-2 mL of sterile 
phosphate-buffered saline (pH 7.2) and, after irradiation 
(200 Gy), injected in the patients. At this moment, cell 
viability ranged from 60 to 80% of the initial tumor cell 
viability. Vaccine injections were intradermic.
RESULTS
 In both patients, we observed stabilization of 
the lesions after sunitinib was given. After radical ne-
phrectomy, no surgical complications were observed 
and complete wound healing occurred.
 Patient 1 - Sixty days after surgery, we 
observed a major decrease of pleural effusion and 
stabilization of lung lesions (Figures 2 and 3). A 
120-day control test repeated those findings and 
showed a reduction of the right lung and pleural le-
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sions. Complete disappearance of the small left lung 
lesions was observed. The patient continued clinical 
follow-up with stabilized lesions until the last visit, 
with no new symptoms.
 Patient 2 - We observed a partial regression 
of the lung lesions as well as a significant and con-
tinuous decrease of the cervical mass, as shown in 
Figure-4.
 Until their last follow-up, both patients were 
kept on treatment with DC vaccine therapy and the 
use of sunitinib daily, with a 7-day interval every 4 
weeks, with an apparent stable disease.
COMMENTS
 Futures strategies for the treatment of meta-
static RCC will try to aggregate several drug therapies 
to act on different pathways.
 This treatment with DC has the advantage 
of presenting minimum adverse events, providing 
a better quality of life for patients, in contrast to the 
usual therapy with cytokines that, in spite of present-
ing objective responses, is associated with serious 
side effects, which can lead to poor quality of life or 
even death. DC initiates an immune response and, 
nowadays, we can generate these cells in the labora-
tory, providing a cancer therapy (7). Kugler et al. 
have published good results with stabilization of renal 
metastatic lesions after the association of surgical 
treatment with DC vaccines for metastatic RCC (8). A 
study with DC vaccine alone, published by Barbuto et 
al. (10), for the treatment of metastatic RCC showed 
stabilization of the disease in 71% of the patients in 
median 6.7 months of follow-up (5-21 months).
 The safety and effectiveness of these tar-
geted drugs are well documented in current literature 
with metastatic RCC stabilization for about 5.5 to 
Table 1 – Patient’s characteristics, management and follow-up.
Patient 1 Patient 2
Age (years) 55 62
Initial symptom 6 months with cough Cervical mass and loss of weight
Metastasis location Pulmonary, mediastinal, and pleural 
effusion.
Pulmonary, cervical and supraclavicular
Comorbities Hypertension and diabetes mellitus type 2 -
Time using sunitinib 
before surgery 30 days 30 days
Surgical treatment Videolaparoscopic radical left 
nephrectomy Open radical left nephrectomy
Pathologic examination Clear cell RCC , Fuhrman IV, positive 
for microvascular invasion, lymph node 
metastasis, tumor size: 7cm
Clear cell RCC , Fuhrman IV,  positive for 
microvascular invasion, lymph node metas-
tasis, tumor size: 12cm
Vaccine doses 7 8
Restart delay in the use of  
sunitinib after surgery 21 days 14 days
Complications – surgical 
wound - -
Imaging Partial regression / Pleural efusion 
regression 
Partial regression
Side-effects Hand-foot syndrome Weakness / diarrhea
Time of  follow-up 9 months 10 months
RCC  = renal cell carcinoma.
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11 months with sorafenib (12) and sunitinib (13), 
respectively. The use of DC vaccine has also shown 
promising results in some reported cases in the lit-
erature (9).
 The use of DC vaccine in association with tar-
geted drugs is controversial and was first assumed that 
it could be used with sunitinib alone, (14) although 
it could also be used with sorafenib as demonstrated 
by Alfaro et al. (15).
 The use of targeted therapy with DC vaccine 
after nephrectomy in metastatic RCC disease has not 
yet been published. It shows a possible synergy by 
those two approaches, leading to a more promising 
Figure 1 – Patient 1: Thoracic CT scan showing metastatic 
nodules.
Figure 2 – Patient 1: CT scan showing pleural effusion among 
pleural metastasis.
Figure 3 – Patient 1: CT scan with regression of the pleural ef-
fusion without thoracocentesis.
Figure 4 – A) Patient 2: Coronal CT scan showing a cervical node metastasis. B) Coronal CT scan presenting clear regression of 
cervical mass after treatment.
A B
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anti-tumoral control using two distinct mechanisms of 
action, in combination with a cytoreductive surgery.
 Even though these multi-drug therapies for 
metastatic RCC disease were a good and reason-
able possibility, the combination of sunitinib with 
sorafenib failed to prove its effectiveness (16). De-
spite important progress in metastatic RCC after the 
introduction of targeted therapy, clinically significant 
benefit is limited. Several issues still remain unclear, 
lacking proper prospective clinical trials for an evi-
dence-based guideline (17).
 Sunitinib is a tirosine kinase inhibitor with 
double action: antiproliferative and antiangiogenic, 
(12) Bevacizumab is another inhibitor of angiogenesis 
(18) and tensirolimus a specific inhibitor of the mam-
malian target of rapamycin kinase (19). Apparently, 
any of these drugs could be used in association with 
DC vaccine based on the Alfaro et al. study (15).
 Cytoreductive nephrectomy in metastatic 
RCC has shown benefits in a significant number of 
patients improving disease-specific survival (20). 
These newly developed targeted-drug therapies may 
bring new expectations for these patients with a poor 
life expectancy.
 Until now, at ten months follow-up, we 
could observe a regression of metastatic lesions and 
stabilization of the disease in imaging tests with DC 
vaccine combined to a targeted-drug therapy. This 
may represent a new and promising strategy of treat-
ment for clinical use, since median life expectancy 
for metastatic RCC using sunitinib alone or interferon 
was 5.3 and 4 months, respectively, as reported by 
Motzer et al. (21,22). Novel insights into immunology 
and biology of the tumor have accelerated research 
on vaccines, which demonstrated significant efficacy 
as antitumoral agents (23).
 The immune response obtained with DC 
vaccine associated with the antiangiogenic effect 
of sunitinib appear to present a new horizon in the 
therapy of metastatic RCC pointing towards a new 
option for treatment of a potential lethal disease as 
demonstrated in this small series of cases.
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EDITORIAL COMMENT
 Renal cell carcinoma is frequently asymp-
tomatic in its early stages. As a consequence, a high 
percentage of patients is diagnosed with metastatic 
disease at initial presentation. In advanced stages 
treatment results are extremely poor with an overall 
median survival of less than one year. Nephrectomy 
and/or systemic treatment with cytotoxic chemo-
therapy have poor or no effectiveness.
 Recently, the use of molecular targeted ther-
apies have shown survival benefits for patients with 
metastatic renal cell carcinoma. A new possibility is 
a consequence of the development of dendritic cells 
in vitro which are potent antigen-presenting cells. 
Some studies have shown significant response in 
metastatic disease using vaccines based on dendritic 
cells hybridized with cells from the tumor itself.
 Dr. Dall’Oglio et al. report a novel initial ex-
perience with two patients treated with multi-modal-
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cytoreductive nephrectomy, and hybrid dendritic cell 
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vaccine. Follow-up of 9 and 10 months have demon-
strated stable disease in both, as shown by imaging 
and clinical findings, with no further treatment re-
quired.
 This is a very promising result. We hope 
that new trials with higher number of patients and 
longer follow-up confirm the benefit in the immune 
response obtained with dendritic cell vaccine com-
bined with the antiangiogenic effect of sunitinib in 
the treatment of metastatic renal cell carcinoma.
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EDITORIAL COMMENT
 Renal cell carcinoma (RCC) still is a 
major health problem and almost half of the pa-
tients have locally advanced or metastatic disease at 
the time of the diagnosis. Recently, targeting agents 
have demonstrated benefits in progression free-sur-
vival and overall survival in patients bearing a meta-
static RCC. Currently, these drugs are recommended 
as first and second line standard of care in metastatic 
RCC (1). But despite proven efficacy, complete re-
sponse is rarely seen. Therefore, new strategies and 
treatment modalities are required to optimize RCC 
outcomes.
 Several therapeutic strategies are under 
investigation in urologic oncology. Urologists are 
familiar with immunotherapy, since these interven-
tions have long been utilized for kidney (IL-2, IFN 
alfa) and bladder cancer (BCG) treatments. Theo-
retically, vaccinated patients could develop an im-
mune surveillance, able to lead either to a postponed 
recurrence or prolonged cancer specific-survival. 
At present, therapeutic potential of vaccines against 
metastatic RCC is limited as highlighted by the au-
thors. Nevertheless, metastatic RCC patients treated 
with DC vaccines showed promising results in sev-
eral phase I/II trials (2). In an investigative scenario, 
considerable interest exists in simultaneous delivery 
antiangiogenic drugs and vaccines. The tumor im-
mune-suppressive microenvironment could be a 
possible explanation to why tumors can evade the 
immune system. Tyrosine kinase inhibitors might 
sinergically contribute to restore the impaired tumor-
mediated immune response and thereby improve 
vaccine efficacy.
 In the present report, a word of caution must 
be emphasized to underline the major limitation of 
this combined antitumor strategy. Since both pa-
tients received sunitinib, we cannot confirm if the 
clinical response presented by these two patients 
was anyhow impacted by the concomitant use of DC 
vaccine. Certainly, this issue can only be addressed 
in a future phase 3 clinical trial.
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